TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
EMPLOYEES
Merck Life Science AB
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
1,192,798
|
1,288,447
|
1,322,751 |
| Financial expenses |
187
|
0
|
1,225 |
| Earnings before taxes |
635,723
|
700,894
|
711,031 |
| EBITDA |
606,002
|
662,195
|
707,339 |
| Total assets |
791,412
|
1,436,153
|
917,612 |
| Current assets |
777,637
|
1,422,316
|
902,830 |
| Current liabilities |
46,471
|
95,888
|
133,124 |
| Equity capital |
733,999
|
1,329,474
|
773,679 |
| - share capital |
10,300
|
10,300
|
10,300 |
| Employees (average) |
40
|
48
|
46 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
92.7%
|
92.6%
|
84.3% |
| Turnover per employee |
29,820
|
26,843
|
28,755 |
| Profit as a percentage of turnover |
53.3%
|
54.4%
|
53.8% |
| Return on assets (ROA) |
80.4%
|
48.8%
|
77.6% |
| Current ratio |
1673.4%
|
1483.3%
|
678.2% |
| Return on equity (ROE) |
86.6%
|
52.7%
|
91.9% |
| Change turnover |
-95,649
|
-34,304
|
393,516 |
| Change turnover % |
-7%
|
-3%
|
42% |
| Chg. No. of employees |
-8
|
2
|
17 |
| Chg. No. of employees % |
-17%
|
4%
|
59% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.